Padula William V, Heru Shiona, Campbell Jonathan D
Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, 624 N. Broadway, Baltimore, MD, 21205, USA.
Commonwealth of Massachusetts Group Insurance Commission (GIC), Boston, MA, USA.
J Gen Intern Med. 2016 Apr;31(4):394-401. doi: 10.1007/s11606-015-3529-6. Epub 2015 Oct 19.
Recently, the Massachusetts Group Insurance Commission (GIC) prioritized research on the implications of a clause expressly prohibiting the denial of health insurance coverage for transgender-related services. These medically necessary services include primary and preventive care as well as transitional therapy.
To analyze the cost-effectiveness of insurance coverage for medically necessary transgender-related services.
Markov model with 5- and 10-year time horizons from a U.S. societal perspective, discounted at 3% (USD 2013). Data on outcomes were abstracted from the 2011 National Transgender Discrimination Survey (NTDS).
U.S. transgender population starting before transitional therapy.
No health benefits compared to health insurance coverage for medically necessary services. This coverage can lead to hormone replacement therapy, sex reassignment surgery, or both.
Cost per quality-adjusted life year (QALY) for successful transition or negative outcomes (e.g. HIV, depression, suicidality, drug abuse, mortality) dependent on insurance coverage or no health benefit at a willingness-to-pay threshold of $100,000/QALY. Budget impact interpreted as the U.S. per-member-per-month cost.
Compared to no health benefits for transgender patients ($23,619; 6.49 QALYs), insurance coverage for medically necessary services came at a greater cost and effectiveness ($31,816; 7.37 QALYs), with an incremental cost-effectiveness ratio (ICER) of $9314/QALY. The budget impact of this coverage is approximately $0.016 per member per month. Although the cost for transitions is $10,000-22,000 and the cost of provider coverage is $2175/year, these additional expenses hold good value for reducing the risk of negative endpoints--HIV, depression, suicidality, and drug abuse. Results were robust to uncertainty. The probabilistic sensitivity analysis showed that provider coverage was cost-effective in 85% of simulations.
Health insurance coverage for the U.S. transgender population is affordable and cost-effective, and has a low budget impact on U.S. society. Organizations such as the GIC should consider these results when examining policies regarding coverage exclusions.
最近,马萨诸塞州团体保险委员会(GIC)将一项明确禁止拒绝为与变性相关服务提供医疗保险的条款的影响研究列为优先事项。这些医疗必需服务包括初级和预防性护理以及过渡性治疗。
分析为医疗必需的变性相关服务提供保险的成本效益。
从美国社会视角出发,采用5年和10年时间范围的马尔可夫模型,按3%贴现(2013年美元)。结局数据摘自2011年全国变性者歧视调查(NTDS)。
开始接受过渡性治疗前的美国变性人群体。
与为医疗必需服务提供医疗保险相比,不提供健康福利。这种保险覆盖可导致激素替代疗法、性别重置手术或两者皆有。
成功过渡或出现负面结局(如感染艾滋病毒、抑郁、自杀倾向、药物滥用、死亡)的每质量调整生命年(QALY)成本,取决于保险覆盖情况或不提供健康福利,支付意愿阈值为100,000美元/QALY。预算影响解释为美国每人每月成本。
与不为变性患者提供健康福利(成本23,619美元;6.49个QALY)相比,为医疗必需服务提供保险成本更高但效益更好(成本31,816美元;7.37个QALY),增量成本效益比(ICER)为9314美元/QALY。这种保险覆盖的预算影响约为每人每月0.016美元。尽管过渡成本为10,000 - 22,000美元,提供者保险成本为每年2175美元,但这些额外费用对于降低负面终点风险——感染艾滋病毒、抑郁、自杀倾向和药物滥用——具有很高价值。结果对不确定性具有稳健性。概率敏感性分析表明,在85%的模拟中,提供者保险具有成本效益。
为美国变性人群体提供医疗保险是可承受且具有成本效益的,并且对美国社会的预算影响较小。GIC等组织在审查有关保险排除条款的政策时应考虑这些结果。